logo

Neon Therapeutics, Inc. (NTGN)



Trade NTGN now with
  Date
  Headline
12/6/2018 7:14:11 AM Neon Therapeutics And Apexigen Announce First Patient Dosed In Neon’s NT-003 Phase 1b Combination Trial Of NEO-PV-01
11/12/2018 4:20:22 PM Neon Therapeutics Q3 Loss/share $0.67 Vs. Loss $9.59 Year Ago
10/22/2018 6:01:07 AM Neon Therapeutics Presents Data From Ongoing Phase 1b NT-001 Clinical Trial At ESMO 2018 Congress
8/21/2018 4:24:52 PM Neon Therapeutics Appoints Jolie Siegel As General Counsel